Onconetix, Inc. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Onconetix, Inc. treasury stock, value, acquired, cost method for the quarter ending 2023-06-30 was $25.53K.
- Onconetix, Inc. treasury stock, value, acquired, cost method for the quarter ending 2023-03-31 was $33.45K.
- Onconetix, Inc. treasury stock, value, acquired, cost method for fiscal 2023 was $58.98K, a 89.59% decline from fiscal 2022.
- Onconetix, Inc. treasury stock, value, acquired, cost method for fiscal 2022 was $566.81K.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2023-12-31 | $58.98K 10-K · filed 2025-06-02 | |
| 2023-06-30 | $25.53K 10-Q · filed 2024-12-10 | |
| 2023-03-31 | $33.45K 10-Q · filed 2024-12-10 | |
| 2022-12-31 | $566.81K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |